Sun, Feb 1, 2015, 3:44 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

  • medicalstarv medicalstarv Jun 17, 2013 11:52 AM Flag

    (IGXT) MCap $28 M/ Price 0.55 /NDA acceptance this Week/ 10 Drugs in Late Stage !!!

    unknown gem with brutal upside Potential........IGXT´s Monster Pipeline :

    Product ......Application......... Status of Development

    INT0004/2006 Antidepressant -- US launch in 4Q 2012

    INT0008/2007 Migraine -- Submit NDA in March 2013

    INT0007/2006 Erectile Dysfunction -- NDA filing later in 2013

    INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing later in 2013

    INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA filing later in 2013

    INT0020/2010 Insomnia -- in Pivotal Study

    INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

    INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

    INT0030/2011 Animal health -- in Pivotal Study

    INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good News is Out today guys

      On announcing the news, IntelGenx' President and CEO Dr. Horst Zerbe commented, "We are very pleased with the FDA's confirmation that our anti-migraine film application has been accepted for review. We believe that our Rizatriptan film is the first oral film product for the treatment of migraine for which a 505(b)(2) NDA has been submitted to FDA. We consider that the product has significant market potential as it is therapeutically equivalent to Maxalt-MLT(R) orally disintegrating tablets, is easy to use, and offers significant cost advantages over orally disintegrating tablets."

      IntelGenx had previously announced a successful pre-NDA meeting with the FDA following the completion of a bioequivalency study demonstrating that its oral film product is bioequivalent with Maxalt MLT(R), a leading branded anti-migraine product manufactured by Merck. According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012. The thin-film formulation of Rizatriptan has been developed in accordance with the co-development and commercialisation agreement with RedHill (RDHL) (RDHL) using IntelGenx' proprietary immediate release "VersaFilm(TM)" drug delivery technology.

      IntelGenx' orally disintegrating film consists of a thin (30 -- 50 um) polymeric film which disintegrates rapidly upon oral administration, thereby releasing the active drug Rizatriptan and making it available for rapid absorption. The film does not require water for administration.

7.81-0.05(-0.64%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.